Microlearning

Breast Cancer

New Education

This new series of case-based microlearning courses are designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in applying practice-changing updates regarding HER2-low and HER2-ultralow advanced breast cancer.

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: IHC Testing and Interpretation

This is the first of three activities and focuses on HER2 classification, tracking, and reporting considerations for HER2 IHC testing and interpretations in HER2-low breast cancers.

Course Topics Include:

  • HER2 immunohistochemistry
  • Impact of pre-analytical variables on HER2 immunohistochemistry
  • CAP/ASCO 2023 HER2 immunohistochemistry guidelines
Claim Credit

 

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Emerging Science and Current Treatment

In the second portion of this three-part activity we focus on the emerging science of HER2-low and HER2-ultralow then go into current treatment for HER2-low and HER2-ultralow patients.

Course Topics Include:

  • Emerging science around HER2-low and HER2-ultralow
  • Current and evolving treatment strategies for patients with HER2-low and HER2-ultralow breast cancer
Claim Credit

 

Best Practices in HER2-low and HER2-ultralow Advanced Breast Cancer: Reproducibility of Testing

In this final part of the three activities, the focus is on reproducibility of testing and clinical significance of HER2-low and HER2-ultralow.

Course Topics Include:

  • Interobserver variability in HER2 IHC scoring
  • Clinical significance of HER2-low and HER2-ultralow
Claim Credit

 

This microlearning series is supported by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.

Challenges in Testing Across the HER2+ Breast Cancer Spectrum

This CME/CMLE-accredited, case-based microlearning activity is designed to help pathologists and laboratory professionals increase their knowledge, skills, and competence in testing and diagnosing breast cancer across the HER2 spectrum.

Every few days, participants will be emailed or sent several questions through the Qstream app. Each question consists of an authentic patient case/scenario and an assessment question with 3-5 multiple-choice answers designed to help you make an appropriate diagnosis/recommendation.

This case-based microlearning activity includes the following topics:

  • Best practices in IHC interpretation across the HER2 spectrum
  • Clinical practice guidelines for IHC and ISH testing
  • The science and emerging evidence around HER2-low breast cancer
  • HER2 classification, tracking, and reporting considerations
  • Emerging treatment options for patients with HER2-low breast cancer
  • The critical importance of communication within the multidisciplinary cancer care team

Learning Objectives

Upon completion of this activity, you should be able to:

  • Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines
  • Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer
  • Update laboratory processes and procedures (e.g., related to identification, tracking, and reporting) to prepare for the anticipated emergence of HER2-low as a diagnostic category of breast cancer
  • Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer

Faculty

Swikrity U. Baskota, MD, Assistant Professor of Pathology and Cell Biology, Columbia University Medical Center

Poonam Vohra, MD, FASCP, Associate Professor, Anatomic Pathology, University of California, San Francisco

Faculty Disclosures: Swikrity U. Baskota, MD, and Poonam Vohra, MD, FASCP, have no relevant financial relationships to disclose.

Credits

The activity offers 1.0 CME/CMLE credit.

Microlearning

Challenges in Testing Across the HER2+ Breast Cancer Spectrum

Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Register Now

Register

This course allows you to claim credit once you have completed the microlearning education in QStream and received your completion notice via email. Do not attempt to claim credit until you have completed the microlearning education in QStream. To register, take the following steps.

  • Visit ASCP’s Qstream site.
  • Sign up for a Qstream account.
  • Enroll in the case-based microlearning series "Challenges in Testing Across the HER2+ Breast Cancer Spectrum"

CME Information

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The ASCP designates this online microlearning activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.